We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00381264
First Posted: September 27, 2006
Last Update Posted: February 15, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NEMA Research, Inc.
  Purpose
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to Multiple Sclerosis.

Condition Intervention Phase
Multiple Sclerosis Drug: Cesamet™ (nabilone) Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by NEMA Research, Inc.:

Primary Outcome Measures:
  • The Average Pain Score at target site.

Secondary Outcome Measures:
  • The Worst Pain Score at target site.
  • The Pain at Night Score at target site.
  • Quality of Life measures.
  • Patient satisfaction with treatment.
  • Safety will be assessed through the collection of AEs and vital signs.

Estimated Enrollment: 23
Study Start Date: September 2006
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this study is to determine the safety and efficacy of Cesamet™ in the symptomatic treatment of pain due to Multiple Sclerosis.

This is a phase IV, multi-center, open label outpatient clinical trial evaluating Cesamet™ treatment for control of pain due MS. The study has two phases: a Pretreatment Phase and a Treatment Phase.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients diagnosed with MS
  • Chronic daily pain present for at least 2 months.
  • On stable analgesic regimen for one month
  • Baseline pain score greater than 40mm on a visual analog scale.

Exclusion Criteria:

  • Hypersensitivity to compounds in study drug or similar drugs
  • Pregnant or lactating females
  • Drug or alcohol abuse
  • Unstable medical condition
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00381264


Locations
United States, Florida
South Florida Medical Research
Aventura, Florida, United States, 33180
Sunrise Clinical Research, Inc.
Hollywood, Florida, United States, 33021
Naples Anesthesia and Pain Associates
Naples, Florida, United States, 34108
Lazlo Mate, MD
West Palm Beach, Florida, United States, 33407
Sponsors and Collaborators
NEMA Research, Inc.
Investigators
Principal Investigator: Joseph V Pergolizzi, MD NEMA Research, Inc.
Study Director: Charlotte A Richmond, PhD Nema Research
  More Information

Additional Information:
Responsible Party: Joseph Pergolizzi, MD, NEMA Research
ClinicalTrials.gov Identifier: NCT00381264     History of Changes
Other Study ID Numbers: CB1 Study 002
First Submitted: September 25, 2006
First Posted: September 27, 2006
Last Update Posted: February 15, 2008
Last Verified: February 2008

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Nabilone
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs